Cargando…

Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Banik, Debarati, Moufarrij, Sara, Villagra, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539010/
https://www.ncbi.nlm.nih.gov/pubmed/31067680
http://dx.doi.org/10.3390/ijms20092241
_version_ 1783422283352637440
author Banik, Debarati
Moufarrij, Sara
Villagra, Alejandro
author_facet Banik, Debarati
Moufarrij, Sara
Villagra, Alejandro
author_sort Banik, Debarati
collection PubMed
description Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration. Finally, we have included examples of ongoing trials for each of the above categories of HDACis as standalone agents or in combination with immunotherapeutic approaches.
format Online
Article
Text
id pubmed-6539010
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65390102019-06-04 Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Banik, Debarati Moufarrij, Sara Villagra, Alejandro Int J Mol Sci Review Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration. Finally, we have included examples of ongoing trials for each of the above categories of HDACis as standalone agents or in combination with immunotherapeutic approaches. MDPI 2019-05-07 /pmc/articles/PMC6539010/ /pubmed/31067680 http://dx.doi.org/10.3390/ijms20092241 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Banik, Debarati
Moufarrij, Sara
Villagra, Alejandro
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title_full Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title_fullStr Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title_full_unstemmed Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title_short Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
title_sort immunoepigenetics combination therapies: an overview of the role of hdacs in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539010/
https://www.ncbi.nlm.nih.gov/pubmed/31067680
http://dx.doi.org/10.3390/ijms20092241
work_keys_str_mv AT banikdebarati immunoepigeneticscombinationtherapiesanoverviewoftheroleofhdacsincancerimmunotherapy
AT moufarrijsara immunoepigeneticscombinationtherapiesanoverviewoftheroleofhdacsincancerimmunotherapy
AT villagraalejandro immunoepigeneticscombinationtherapiesanoverviewoftheroleofhdacsincancerimmunotherapy